Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biohaven Pharma (BHVN) Tops Q3 EPS by 22c
November 9, 2020 8:10 AM ESTBiohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($2.67), $0.22 better than the analyst estimate of ($2.89). Revenue for the quarter came in at $17.66 million versus the consensus estimate of $19.35 million.
Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "In just over six months from launch, NURTEC ODT is changing the standard treatment paradigm of migraine as reflected by attaining more than 220,000 prescriptions written by over 20,000 health care providers in such a short... More
